Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 18.18%10.28B | 19.38%6.38B | 21.23%2.89B | -8.65%12.2B | -13.31%8.69B | -22.66%5.35B | -25.29%2.39B | -3.45%13.35B | -2.08%10.03B | 8.20%6.92B |
| Operating income | 18.18%10.28B | 19.38%6.38B | 21.23%2.89B | -8.65%12.2B | -13.31%8.69B | -22.66%5.35B | -25.29%2.39B | -3.45%13.35B | -2.08%10.03B | 8.20%6.92B |
| Operating expenses | -16.52%-7.31B | -18.72%-4.58B | -19.50%-2.09B | 12.04%-8.87B | 15.46%-6.28B | 24.55%-3.86B | 26.65%-1.75B | 4.78%-10.08B | 5.61%-7.42B | -3.13%-5.11B |
| Gross profit | 22.49%2.96B | 21.08%1.81B | 25.96%805.68M | 1.78%3.33B | -7.19%2.42B | -17.31%1.49B | -21.33%639.64M | 0.89%3.27B | 9.59%2.61B | 25.69%1.8B |
| Selling expenses | -19.72%-402.55M | -9.50%-240.71M | -5.24%-114.84M | 2.62%-489.15M | 3.30%-336.25M | 4.19%-219.84M | 1.63%-109.12M | -21.45%-502.29M | -27.89%-347.72M | -33.24%-229.45M |
| Administrative expenses | -7.67%-821.93M | -8.76%-538.89M | -10.62%-266.82M | 0.55%-1.04B | -3.38%-763.35M | -3.35%-495.5M | -6.20%-241.2M | -34.58%-1.05B | -38.06%-738.38M | -55.99%-479.44M |
| Research and development expenses | -8.61%-607.16M | -10.99%-385.83M | -12.79%-176.1M | -1.57%-787.19M | -0.06%-559.04M | 5.43%-347.61M | 13.84%-156.13M | 1.13%-774.99M | -2.62%-558.71M | -14.87%-367.56M |
| Profit from asset sales | 158.46%4.88M | 109.90%623.12K | -94.12%116.27K | -266.84%-8.16M | -444.78%-8.34M | -460.15%-6.29M | 303.68%1.98M | 7.15%-2.22M | 267.60%2.42M | 15.39%-1.12M |
| Revaluation surplus | -220.44%-5.15M | -255.42%-4.21M | 94.72%2.34M | -1,382.90%-138.17M | -27.57%4.27M | -43.94%2.71M | -54.46%1.2M | 13.70%10.77M | 849.56%5.9M | 377.09%4.83M |
| -Changes in the fair value of other assets | -220.44%-5.15M | -255.42%-4.21M | 94.72%2.34M | -1,382.90%-138.17M | -27.57%4.27M | -43.94%2.71M | -54.46%1.2M | 13.70%10.77M | 849.56%5.9M | 377.09%4.83M |
| Impairment and provision | -72.46%-287.12M | -86.54%-199.1M | -85.39%-56.19M | -20.65%-286.95M | -7.51%-166.48M | 28.12%-106.73M | 16.68%-30.31M | -16.67%-237.85M | -50.53%-154.85M | -101.27%-148.49M |
| -Other impairment is provision | -72.46%-287.12M | -86.54%-199.1M | -85.39%-56.19M | -20.65%-286.95M | -7.51%-166.48M | 28.12%-106.73M | 16.68%-30.31M | -16.67%-237.85M | -50.53%-154.85M | -101.27%-148.49M |
| Special items of operating profit | 116.85%4.55M | 114.69%3.42M | -27.64%-6.71M | -87.69%88.99M | -110.48%-27M | -112.83%-23.26M | -115.24%-5.25M | 168.47%723.01M | 128.88%257.69M | 160.03%181.24M |
| Operating profit | 55.57%770.78M | 55.50%390.89M | 107.70%164.29M | -56.59%584.32M | -50.09%495.46M | -64.44%251.37M | -71.66%79.1M | 7.42%1.35B | 1.91%992.79M | 19.03%706.87M |
| Financing cost | -31.65%-160.25M | 11.53%-78M | -19.84%-45.29M | -50.14%-191.18M | -20.30%-121.72M | -305.04%-88.17M | -13.81%-37.79M | -53.63%-127.33M | -67.63%-101.18M | 39.58%-21.77M |
| Adjustment items of earning before tax | -64.70%65M | -60.07%73.43M | 1,639.04%64.93M | 8,762.52%199.76M | 22,343.27%184.12M | 4,616.80%183.9M | 251.75%3.73M | 87.38%-2.31M | 468.15%820.4K | -419.18%-4.07M |
| Earning before tax | 21.09%675.53M | 11.30%386.32M | 308.39%183.92M | -51.26%592.9M | -37.49%557.86M | -49.03%347.11M | -81.50%45.04M | 5.60%1.22B | -2.32%892.43M | 21.81%681.03M |
| Tax | -253.19%-134.69M | -108.33%-39.91M | 42.89%-6.7M | 70.50%-11.65M | 43.22%-38.13M | 64.96%-19.16M | 49.58%-11.74M | -525.93%-39.49M | -34.85%-67.16M | -31.13%-54.67M |
| After-tax profit from continuing operations | 4.06%540.85M | 5.63%346.41M | 432.25%177.22M | -50.61%581.25M | -37.02%519.73M | -47.64%327.95M | -84.87%33.3M | 1.35%1.18B | -4.46%825.27M | 21.06%626.36M |
| Earning after tax | 4.06%540.85M | 5.63%346.41M | 432.25%177.22M | -50.61%581.25M | -37.02%519.73M | -47.64%327.95M | -84.87%33.3M | 1.35%1.18B | -4.46%825.27M | 21.06%626.36M |
| Minority profit | 233.75%71.17M | 201.75%50.67M | 203.64%25.52M | 21.47%-94.62M | 3.81%-53.21M | -357.40%-49.8M | -17.70%-24.62M | -1,993.09%-120.5M | -376.99%-55.32M | 341.96%19.35M |
| Profit attributable to shareholders | -18.02%469.68M | -21.71%295.74M | 161.91%151.7M | -47.91%675.88M | -34.94%572.94M | -37.77%377.75M | -75.97%57.92M | 11.18%1.3B | 0.59%880.59M | 15.54%607.01M |
| Basic earnings per share | -18.42%0.62 | -22.00%0.39 | 150.00%0.2 | -47.95%0.89 | -34.48%0.76 | -37.50%0.5 | -75.00%0.08 | 11.04%1.71 | 0.00%1.16 | 15.94%0.8 |
| Diluted earnings per share | -18.42%0.62 | -22.00%0.39 | 150.00%0.2 | -47.95%0.89 | -34.48%0.76 | -37.50%0.5 | -75.00%0.08 | 11.04%1.71 | 0.00%1.16 | 15.94%0.8 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- |
| Auditor | -- | -- | -- | KPMG Huazhen Certified Public Accountants (Special General Partnership) | -- | -- | -- | KPMG Huazhen Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.